study the effect of radiotherapy to the primary lesion after first line systemic therapy in metastatic non-small cell lung cancer patients.
Metastatic non-small cell lung cancer patients after receiving their first line systemic therapy according to their genetic mutation will be randomized to follow up versus radiotherapy to the primary lesion.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
75
first line systemic therapy according to the genetic mutation 0f the patient
Hypo-fractionated radiotherapy to the primary lesion
Medicine
Shibīn al Kawm, Menoufia, Egypt
progression free survival
time from randomization till disease progression
Time frame: six months
patients quality of life
using the European Organization for Research and Treatment of Cancer core quality of life questionnaire, the EORTC QLQ-C30
Time frame: six months
overall survival
time from randomization till death from any cause
Time frame: six months
patients toxicity
number of participants suffer of different toxicity grades according to Common toxicity criteria of adverse events
Time frame: six months
patients pattern of failure
Number of Participants suffer of disease progression in the primary site vs other newly developed sites
Time frame: six months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.